Vaxart, Inc. (VXRT) NASDAQ

0.45

-0.0425(-8.59%)

Updated at June 30 04:00PM

Currency In USD

Vaxart, Inc.

Address

170 Harbor Way

South San Francisco, CA 94080

United States of America

Phone

650 550 3500

Sector

Healthcare

Industry

Biotechnology

Employees

105

First IPO Date

December 11, 1981

Key Executives

NameTitlePayYear Born
Mr. Steven LoPresident, Chief Executive Officer & Director879,3271967
Dr. Sean N. Tucker Ph.D.Senior Vice President & Chief Scientific Officer622,4391968
Dr. James F. Cummings M.D.Chief Medical Officer679,9431967
Mr. Phillip Eric LeeChief Financial Officer, Principal Financial Officer & Principal Accounting Officer01988
Dr. Raymond D. Stapleton Jr., Ph.D.Chief Technology Officer01972
Mr. Edward B. BergSenior Vice President & General Counsel01965
Ms. Laurie HastingsSenior Vice President of Human Resources0N/A
Ms. Shaily Jaini GargSenior Vice President of Clinical Development & Project Management0N/A
Dr. Rajesh Kapoor Ph.D.Senior Vice President of Quality0N/A

Description

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.